Experiment 1
Subjects
- Location of subjects
- France
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Antimicrobial agent antibiotic,antibiotics,Antibiotika,Antibiotikum,antibiotique,antimicrobial,antimicrobial agents,microbicide,microbicides,Antimicrobial agent,antimicrobial agent
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Negative control group (CLT)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- moxifloxacin treated group (MXF)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- healthy male and female volunteers aged >18 years
- Group 0 sample size Number of subjects in the control (unexposed) group
- 8
- Group 1 sample size Number of subjects in the case (exposed) group
- 14
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 3 months
Lab analysis
- Sequencing type
- WMS
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Mass spectrometry
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Mann-Whitney (Wilcoxon)
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
Alpha Diversity
- Richness Number of species
- decreased
Signature 1
Source: Supplementary table 3, Supplementary figure 1
Description: A detailed analysis of the MGSs that differed significantly between treatment groups
Abundance in Group 1: increased abundance in moxifloxacin treated group (MXF)
| NCBI | Quality Control | Links |
|---|---|---|
| Archaea | ||
| Blautia |
Revision editor(s): WikiWorks
Signature 2
Source: Supplementary table 3, Supplementary figure 1
Description: A detailed analysis of the MGSs that differed significantly between treatment groups
Abundance in Group 1: decreased abundance in moxifloxacin treated group (MXF)
Experiment 2
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- moxifloxacin treated group (MXF)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- DAV132+moxifloxacin treated group (MXF+DAV132)
- Group 0 sample size Number of subjects in the control (unexposed) group
- 14
Lab analysis
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- Not specified
Alpha Diversity
- Richness Number of species
- increased
Signature 1
Source: Supplementary table 3, Supplementary figure 1
Description: A detailed analysis of the MGSs that differed significantly between treatment groups
Abundance in Group 1: increased abundance in DAV132+moxifloxacin treated group (MXF+DAV132)
Revision editor(s): WikiWorks
Signature 2
Source: Supplementary table 3, Supplementary figure 1
Description: A detailed analysis of the MGSs that differed significantly between treatment groups
Abundance in Group 1: decreased abundance in DAV132+moxifloxacin treated group (MXF+DAV132)
| NCBI | Quality Control | Links |
|---|---|---|
| Blautia |
Revision editor(s): WikiWorks
Experiment 3
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Negative control group (CLT)
- Group 0 sample size Number of subjects in the control (unexposed) group
- 8
Lab analysis
Statistical Analysis
Alpha Diversity
- Richness Number of species
- unchanged
Signature 1
Source: Supplementary table 3, Supplementary figure 1
Description: A detailed analysis of the MGSs that differed significantly between treatment groups
Abundance in Group 1: increased abundance in DAV132+moxifloxacin treated group (MXF+DAV132)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacillota | ||
| Lachnospiraceae |
Revision editor(s): WikiWorks
Signature 2
Source: Supplementary table 3, Supplementary figure 1
Description: A detailed analysis of the MGSs that differed significantly between treatment groups
Abundance in Group 1: decreased abundance in DAV132+moxifloxacin treated group (MXF+DAV132)
| NCBI | Quality Control | Links |
|---|---|---|
| Bilophila wadsworthia | ||
| Bifidobacterium adolescentis | ||
| Intestinibacter bartlettii | ||
| Bifidobacterium pseudocatenulatum | ||
| Catenibacterium | ||
| Flavonifractor plautii |
Revision editor(s): WikiWorks
